164 related articles for article (PubMed ID: 18444924)
1. Combined islet and hematopoietic stem cell allotransplantation: a clinical pilot trial to induce chimerism and graft tolerance.
Mineo D; Ricordi C; Xu X; Pileggi A; Garcia-Morales R; Khan A; Baidal DA; Han D; Monroy K; Miller J; Pugliese A; Froud T; Inverardi L; Kenyon NS; Alejandro R
Am J Transplant; 2008 Jun; 8(6):1262-74. PubMed ID: 18444924
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat.
Itakura S; Asari S; Rawson J; Ito T; Todorov I; Liu CP; Sasaki N; Kandeel F; Mullen Y
Am J Transplant; 2007 Feb; 7(2):336-46. PubMed ID: 17283484
[TBL] [Abstract][Full Text] [Related]
3. Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation.
Pathak S; Meyer EH
Front Immunol; 2020; 11():612737. PubMed ID: 33658995
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem-cell transplantation, mixed chimerism, and tolerance in living related donor renal allograft recipients.
Trivedi HL; Vanikar AV; Modi PR; Shah VR; Vakil JM; Trivedi VB; Khemchandani SI
Transplant Proc; 2005 Mar; 37(2):737-42. PubMed ID: 15848518
[TBL] [Abstract][Full Text] [Related]
5. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice.
Guo Z; Wu T; Sozen H; Pan Y; Heuss N; Kalscheuer H; Sutherland DE; Blazar BR; Hering BJ
Transplantation; 2003 Apr; 75(7):909-15. PubMed ID: 12698073
[TBL] [Abstract][Full Text] [Related]
6. Targeting cells causing split tolerance allows fully allogeneic islet survival with minimal conditioning in NOD mixed chimeras.
Al-Adra DP; Pawlick R; Shapiro AM; Anderson CC
Am J Transplant; 2012 Dec; 12(12):3235-45. PubMed ID: 22974315
[TBL] [Abstract][Full Text] [Related]
7. Increasing donor chimerism and inducing tolerance to islet allografts by post-transplant donor lymphocyte infusion.
Liu B; Hao J; Pan Y; Luo B; Westgard B; Heremans Y; Sutherland DE; Hering BJ; Guo Z
Am J Transplant; 2006 May; 6(5 Pt 1):933-46. PubMed ID: 16611329
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
9. Facilitating cells as a venue to establish mixed chimerism and tolerance.
Jacquet EG; Schanie CL; Fugier-Vivier I; Willer SS; Ildstad ST
Pediatr Transplant; 2003 Oct; 7(5):348-57. PubMed ID: 14738294
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic cell-based and non-hematopoietic cell-based strategies for immune tolerance induction in living-donor renal transplantation: A systematic review.
Annamalai C; Kute V; Sheridan C; Halawa A
Transplant Rev (Orlando); 2023 Dec; 37(4):100792. PubMed ID: 37709652
[TBL] [Abstract][Full Text] [Related]
11. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes.
Hering BJ; Kandaswamy R; Ansite JD; Eckman PM; Nakano M; Sawada T; Matsumoto I; Ihm SH; Zhang HJ; Parkey J; Hunter DW; Sutherland DE
JAMA; 2005 Feb; 293(7):830-5. PubMed ID: 15713772
[TBL] [Abstract][Full Text] [Related]
12. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients.
Scharp DW; Lacy PE; Santiago JV; McCullough CS; Weide LG; Boyle PJ; Falqui L; Marchetti P; Ricordi C; Gingerich RL
Transplantation; 1991 Jan; 51(1):76-85. PubMed ID: 1987709
[TBL] [Abstract][Full Text] [Related]
13. MHC-mismatched chimerism is required for induction of transplantation tolerance in autoimmune nonobese diabetic recipients.
Wang M; Racine J; Zhang M; Wu T; Deng R; Johnston H; Shen C; Siswanto K; Zeng D
J Immunol; 2014 Aug; 193(4):2005-15. PubMed ID: 25000982
[TBL] [Abstract][Full Text] [Related]
14. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome.
Leventhal J; Abecassis M; Miller J; Gallon L; Tollerud D; Elliott MJ; Bozulic LD; Houston C; Sustento-Reodica N; Ildstad ST
Transplantation; 2013 Jan; 95(1):169-76. PubMed ID: 23222893
[TBL] [Abstract][Full Text] [Related]
15. Tolerance induction for islet transplantation.
Exner BG; Fowler K; Ildstad ST
Ann Transplant; 1997; 2(3):77-80. PubMed ID: 9869869
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant.
Lin J; Chan WFN; Boon L; Anderson CC
Front Immunol; 2018; 9():837. PubMed ID: 29740442
[TBL] [Abstract][Full Text] [Related]
18. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation.
Leventhal J; Abecassis M; Miller J; Gallon L; Ravindra K; Tollerud DJ; King B; Elliott MJ; Herzig G; Herzig R; Ildstad ST
Sci Transl Med; 2012 Mar; 4(124):124ra28. PubMed ID: 22399264
[TBL] [Abstract][Full Text] [Related]
19. Operational immune tolerance towards transplanted allogeneic pancreatic islets in mice and a non-human primate.
Abdulreda MH; Berman DM; Shishido A; Martin C; Hossameldin M; Tschiggfrie A; Hernandez LF; Hernandez A; Ricordi C; Parel JM; Jankowska-Gan E; Burlingham WJ; Arrieta-Quintero EA; Perez VL; Kenyon NS; Berggren PO
Diabetologia; 2019 May; 62(5):811-821. PubMed ID: 30701283
[TBL] [Abstract][Full Text] [Related]
20. Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings.
Fehr T; Hübel K; de Rougemont O; Abela I; Gaspert A; Güngör T; Hauri M; Helmchen B; Linsenmeier C; Müller T; Nilsson J; Riesterer O; Scandling JD; Schanz U; Cippà PE
Front Immunol; 2022; 13():796456. PubMed ID: 35173720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
